ArticleThe American journal of clinical nutrition2025
Vitamin C status across the spectrum of chronic kidney disease and healthy controls: a cross-sectional study.
Article in The American journal of clinical nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with chronic kidney disease (CKD) are at risk for vitamin C (VitC) deficiency.
objectivesWe aimed to investigate VitC status and its determinants across the spectrum of CKD and healthy individuals.
methodsIn this cross-sectional study, we measured plasma VitC concentrations (<10 μmol/L = deficient, 10‒35 μmol/L = inadequate) in 62 individuals on dialysis, 41 with CKD stage 4/5, 42 kidney transplant recipients (KTRs) (together: CKD population), and in 447 living kidney donors, and 385 healthy controls (together: healthy population). In the CKD population, we assessed VitC intake (<75 mg/d = inadequate) using 24-h dietary recalls. We measured VitC removal by hemodialysis. We investigated potential determinants of plasma VitC with linear regression in the CKD population and in the healthy population separately.
resultsMedian (Q1‒Q3) plasma VitC was highest in healthy controls [58 (43‒69) μmol/L, 14% inadequate/deficient], followed by kidney donors [50 (36‒66) μmol/L, 22% inadequate/deficient], KTR [37 (19‒46) μmol/L, 48% inadequate/deficient], dialysis [33 (19‒47) μmol/L, 58% inadequate/deficient], and CKD stage 4/5 [22 (14‒34) μmol/L, 80% inadequate/deficient]. Daily dietary VitC intake was similar in KTR [55.5 (33.5‒144.2) mg, 55% inadequate] and CKD stage 4/5 [53.0 (23.9‒142.0) mg, 56% inadequate], and higher in dialysis [113 (72‒209) mg, 26% inadequate] due to supplementation. VitC removal was 58 (27‒123) mg in conventional and 128 (97‒156) mg in nocturnal hemodialysis sessions. In the healthy population, estimated glomerular filtration rate was positively associated with plasma VitC [standardized β coefficient: 0.18 (0.08, 0.27), P < 0.001], independent of potential confounders.
conclusionsVitC inadequacy and deficiency are common in CKD. Inadequate intake and removal by dialysis may contribute. In healthy individuals estimated glomerular filtration rate was inversely associated with plasma VitC. Our findings highlight the importance of monitoring VitC status in CKD, and represent a potential target for intervention. Future research could evaluate the potential health effects of improving VitC status in CKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.